Cleveland BioLabs, Inc. (CBLI) financial statements (2021 and earlier)
Company profile
| Business Address |
73 HIGH STREET BUFFALO, NY 14203 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 8731 - Commercial Physical and Biological Research (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 4 | 9 | 15 | 20 | 3 | 10 | |||
| Cash and cash equivalents | 4 | 4 | 7 | 6 | 3 | 10 | |||
| Short-term investments | 1 | 5 | 8 | 14 | 0 | ||||
| Other undisclosed cash, cash equivalents, and short-term investments | (0) | ||||||||
| Receivables | 0 | 1 | 0 | 1 | 0 | 0 | |||
| Other current assets | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Other undisclosed current assets | 0 | ||||||||
| Total current assets: | 4 | 10 | 16 | 21 | 4 | 11 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Long-term investments and receivables | 4 | ||||||||
| Long-term investments | 4 | ||||||||
| Restricted cash and investments | 0 | 2 | |||||||
| Other noncurrent assets | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Other undisclosed noncurrent assets | 3 | ||||||||
| Total noncurrent assets: | 0 | 0 | 0 | 0 | 6 | 4 | |||
| TOTAL ASSETS: | 5 | 10 | 16 | 21 | 10 | 15 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 1 | 1 | 2 | 2 | 3 | 3 | |||
| Accounts payable | 0 | 0 | 0 | 0 | 1 | 1 | |||
| Accrued liabilities | 1 | 1 | 2 | 2 | 2 | 2 | |||
| Debt | 3 | 0 | |||||||
| Derivative instruments and hedges, liabilities | 0 | 1 | 1 | 4 | 1 | 1 | |||
| Deferred revenue and credits | ✕ | ✕ | 0 | 0 | 1 | ||||
| Total current liabilities: | 1 | 2 | 3 | 6 | 7 | 6 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 0 | ||||||||
| Capital lease obligations | ✕ | 0 | |||||||
| Liabilities, other than long-term debt | 0 | 0 | |||||||
| Other liabilities | 0 | 0 | |||||||
| Other undisclosed noncurrent liabilities | 1 | 7 | |||||||
| Total noncurrent liabilities: | 0 | 0 | 1 | 7 | |||||
| Total liabilities: | 1 | 2 | 3 | 6 | 8 | 13 | |||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | (1) | 2 | 8 | 10 | (2) | (10) | |||
| Common stock | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Treasury stock, value | (1) | ||||||||
| Additional paid in capital | 163 | 163 | 159 | 159 | 133 | 126 | |||
| Accumulated other comprehensive income (loss) | (1) | (1) | (1) | (0) | (0) | 0 | |||
| Accumulated deficit | (164) | (160) | (151) | (148) | (134) | (136) | |||
| Stockholders' equity attributable to noncontrolling interest | 5 | 5 | 5 | 5 | 3 | 11 | |||
| Total stockholders' equity: | 4 | 7 | 13 | 15 | 2 | 2 | |||
| TOTAL LIABILITIES AND EQUITY: | 5 | 10 | 16 | 21 | 10 | 15 | |||
Income statement (P&L) ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Gross profit: | 1 | 2 | 4 | 3 | 4 | 8 | ||
| Operating expenses | (6) | (8) | (10) | (13) | (18) | (32) | ||
| Operating loss: | (5) | (6) | (6) | (11) | (14) | (23) | ||
| Nonoperating income (expense) | 1 | (4) | 4 | (2) | 14 | 3 | ||
| Investment income, nonoperating | (1) | 14 | ||||||
| Foreign currency transaction gain (loss), before tax | 0 | (0) | 0 | (1) | (1) | |||
| Interest and debt expense | 0 | (0) | ||||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (4) | (10) | (3) | (13) | 0 | (20) | ||
| Loss from equity method investments | (0) | |||||||
| Loss before gain (loss) on sale of properties: | (4) | (10) | (3) | (13) | (0) | (20) | ||
| Other undisclosed net income (loss) | (0) | 0 | 0 | |||||
| Net income (loss): | (4) | (10) | (3) | (13) | 0 | (20) | ||
| Net income (loss) attributable to noncontrolling interest | 0 | 0 | (0) | 0 | 2 | 3 | ||
| Net income (loss) available to common stockholders, diluted: | (4) | (10) | (3) | (13) | 2 | (17) | ||
Comprehensive Income ($ in millions)
| 9/30/2019 TTM | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (4) | (10) | (3) | (13) | 0 | (20) | ||
| Other undisclosed comprehensive income (loss) | (0) | 0 | (0) | 0 | 2 | (0) | ||
| Comprehensive income (loss): | (4) | (10) | (3) | (13) | 2 | (21) | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | 0 | 0 | (0) | 0 | 2 | (3) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (4) | 6 | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (4) | (10) | (3) | (13) | 1 | (18) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.